Apogee Therapeutics News and Activities
Presence
Apogee Therapeutics develops biotechnology medicines for inflammatory and immune diseases. Its main products are antibody-based drug candidates and related research services for patients, healthcare providers, and pharmaceutical partners.
Apogee Therapeutics products and services overview:
- Antibody therapies
- Immunology drugs
- Inflammation treatments
- Respiratory treatments
- Dermatology treatments
- Drug research services
Revenue: ~$0 million
Employees: 120
Headquarters: Waltham, United States (USA)
Apogee Therapeutics is one of the...
Apogee Therapeutics is a company listed under the stock ticker APGE (US).
Acquisition, funding and merger involving Apogee Therapeutics.
- Apogee Therapeutics has just announced a $1 Million fundraising (posted on June 1 2026).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at Apogee Therapeutics
- Michael Henderson, Chief Executive Officer and Director
- Nimish Shah, Director
- Lisa Bollinger, Director
Popular executive movements at Apogee Therapeutics
- Andrew Gottesdiener, Director, has left the company (posted on June 1 2026).
Create your alert
to follow the executive moves at Apogee Therapeutics.
Biotechnology
Apogee Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Apogee Therapeutics
- Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results | Apogee Therapeutics, Inc.
- News | Apogee Therapeutics, Inc.
- Apogee Therapeutics to Participate in Upcoming November Investor Conferences | Apogee Therapeutics, Inc.
- News | Apogee Therapeutics, Inc.
- Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day | Apogee Therapeutics, Inc.
- Publications | Apogee Therapeutics, Inc.
- Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress | Apogee Therapeutics, Inc.
- Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results | Apogee Therapeutics, Inc.
- Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board | Apogee Therapeutics, Inc.
- Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | Apogee Therapeutics, Inc.
- View more press releases Close
Social media about Apogee Therapeutics
- Apogee Therapeutics on Wikipedia, Google News & Yahoo Finance
- Apogee Therapeutics on LinkedIn, X (Twitter) & YouTube
